Additionally, fibroblast growth factor 19 (FGF19) (5–10% of tumors) and vascular endothelial growth factor A (VEGFA) amplifications (5–10%) and DNA methylation in the insulin-like growth factor 2 (IGF2) gene were identified in patients with HCC [29,30,31]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.